Chemotherapy-induced COX-2 upregulation by cancer cells defines their inflammatory properties and limits the efficacy of chemoimmunotherapy combinations

Autor: Charlotte R. Bell, Victoria S. Pelly, Agrin Moeini, Shih-Chieh Chiang, Eimear Flanagan, Christian P. Bromley, Christopher Clark, Charles H. Earnshaw, Maria A. Koufaki, Eduardo Bonavita, Santiago Zelenay

Publikováno v: Nature Communications, Vol 13, Iss 1, Pp 1-17 (2022)

COX-2-mediated prostaglandin E2 (PGE2) release from dying cancer cells contributes to cytotoxic therapy resistance. Here the authors show that cytotoxic drugs induce PGE2 release only in cancer cells with basal COX-2 activity and that pharmacological

Externí odkaz: https://doaj.org/article/2367c05eefed45eabfb5cebec3bd1bde

Data from Anti-Inflammatory Drugs Remodel the Tumor Immune Environment to Enhance Immune Checkpoint Blockade Efficacy

Autor: Santiago Zelenay, Daniela S. Thommen, Ton N. Schumacher, Claus Jørgensen, Shih-Chieh Chiang, Eimear Flanagan, Christian P. Bromley, Antonia Banyard, Adrian Blanco-Gomez, Colin Hutton, Charlotte R. Bell, Eduardo Bonavita, Lisanne M. Roelofsen, Agrin Moeini, Victoria S. Pelly

Identifying strategies to improve the efficacy of immune checkpoint blockade (ICB) remains a major clinical need. Here, we show that therapeutically targeting the COX2/PGE2/EP2-4 pathway with widely used nonsteroidal and steroidal anti-inflammatory d

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::8984675ccc2ee02aad006ca4186bf241
https://doi.org/10.1158/2159-8290.c.6549104.v1

RNA sensing via the RIG-I-like receptor LGP2 is essential for the induction of a type I IFN response in ADAR1 deficiency

Autor: Jorn E Stok, Timo Oosenbrug, Laurens R ter Haar, Dennis Gravekamp, Christian P Bromley, Santiago Zelenay, Caetano Reis e Sousa, Annemarthe G van der Veen

Publikováno v: EMBO Journal, 41(6). WILEY

RNA editing by the adenosine deaminase ADAR1 prevents innate immune responses to endogenous RNAs. In ADAR1-deficient cells, unedited self RNAs form base-paired structures that resemble viral RNAs and inadvertently activate the cytosolic RIG-I-like re

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::717cd54e407206e491278854792a4930
https://pubmed.ncbi.nlm.nih.gov/35156720

Chemotherapy-induced COX-2 upregulation by cancer cells defines their inflammatory properties and limits the efficacy of chemoimmunotherapy combinations

Autor: Charlotte R, Bell, Victoria S, Pelly, Agrin, Moeini, Shih-Chieh, Chiang, Eimear, Flanagan, Christian P, Bromley, Christopher, Clark, Charles H, Earnshaw, Maria A, Koufaki, Eduardo, Bonavita, Santiago, Zelenay

Publikováno v: Nature communications. 13(1)

Cytotoxic therapies, besides directly inducing cancer cell death, can stimulate immune-dependent tumor growth control or paradoxically accelerate tumor progression. The underlying mechanisms dictating these opposing outcomes are poorly defined. Here,

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::ce014396e370dc3ff507090ddd1db8cf
https://pubmed.ncbi.nlm.nih.gov/36120509

DNGR-1 limits Flt3L-mediated antitumor immunity by restraining tumor-infiltrating type I conventional dendritic cells

Autor: Alexis J. Combes, Santiago Zelenay, Christian P. Bromley, Matthew F. Krummel, Ignacio Melero, Paola Brandi, Alfonso R. Sánchez-Paulete, Carlos del Fresno, Manuel Gómez, Elena Hernández-García, Francisco J. Cueto, Michel Enamorado, Ruth Conde-Garrosa, Salvador Iborra, David Sancho, Santos Mañes

Publikováno v: Repisalud
Instituto de Salud Carlos III (ISCIII)
Bromley, C 2021, ' DNGR-1 limits Flt3L-mediated antitumor immunity by restraining tumor-infiltrating type I conventional dendritic cells ', Journal for ImmunoTherapy of Cancer . https://doi.org/10.1136/jitc-2020-002054
Journal for Immunotherapy of Cancer
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 5 (2021)
Journal for immunotherapy of cancer, vol 9, iss 5

Conventional type 1 dendritic cells (cDC1s) are central to antitumor immunity and their presence in the tumor microenvironment associates with improved outcomes in patients with cancer. DNGR-1 (CLEC9A) is a dead cell-sensing receptor highly restricte

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0e719150dc3d908f46d05f4443ec98bd
http://hdl.handle.net/20.500.12105/15091